Scholar Response
Response Fields
| Field | Type | Description | Example |
|---|---|---|---|
| patent_citations | Array of Patent Citation | Referenced by patents | |
| patent_citations_count | Integer | Number of patent citations | 10 |
| lens_id | String | Unique lens identifier | 100-004-910-081-14X |
| created | Date | Record created date | 2016-08-01T00:00:00+00:00 |
| publication_type | String (Publication Types) | Publication Type | journal article |
| publication_supplementary_type | Array of String | Supplementary publication type | ["review"] |
| authors | Array of Author | Authors | |
| title | String | Title of the scholarly work | Malaria |
| external_ids | Array of Ids | The external identifier(s) for a scholarly work (DOI, PubMed ID, PubMed Central ID, Microsoft Academic ID or CORE) | |
| start_page | String | Start page | 893 |
| end_page | String | End page | 916 |
| volume | String | Volume | 32 |
| issue | String | Issue | 4 |
| languages | Array of String | Languages | ["en"] |
| references | List of Reference | References | |
| scholarly_citations | List of Lens Ids | Scholarly Citations | ["091-720-300-990-437"] |
| chemicals | List of Chemical | Chemicals | |
| clinical_trials | List of Clinical Trial | Clinical Trials | |
| fields_of_study | List of String | Fields Of Study | ["Immunology", "Malaria"] |
| source_urls | List of Source URL | Source Urls | |
| abstract | String | Scholarly work abstract text | |
| date_published | Date | Date of publication | 2009-05-22 |
| date_published_parts | Array of Integer | Consist of year, month and day | [1974, 1, 6] |
| year_published | Integer | Year of publication | 1986 |
| conference | Conference | The conference instance or edition | |
| author_count | Integer | Number of Authors | 4 |
| references_count | Integer | The number of works in the reference list of a scholarly work | 2 |
| scholarly_citations_count | Integer | The number of scholarly works that cite this scholarly work | 3 |
| open_access | Open Access | ||
| source | Source | Source publication in which the scholarly work appears | |
| keywords | Array of String | Keywords | |
| mesh_terms | Array of MeSH Term | MeSH term | |
| funding | Array of Funding | Funding |
Patent Citation
| Field | Type | Description | Example |
|---|---|---|---|
| lens_id | String | Unique lens identifier | 141-171-521-309-804 |
Author
| Field | Type | Description | Example |
|---|---|---|---|
| collective_name | String | Author Collective Name | |
| first_name | String | The author’s first name | Alexander |
| last_name | String | The author’s last name | Kupco |
| initials | String | Author Initials | A |
| affiliations | Array of Affiliation | The institution/affiliations associated with Author. | |
| ids | Array of Ids | Author’s MAG, ORCID identifiers | [{"type": "magid", "value": "1234567890"}] |
Affiliation
| Field | Type | Description | Example |
|---|---|---|---|
| name | String | The institution associated with the author affiliations. | Stony Brook University |
| name_original | String | The author’s original affiliation including the institution name and address. | School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts USA |
| grid_id | String | Affiliation grid id. NB This field is deprecated, please use the ids field instead. | grid.9018.0 |
| country_code | String | Comma separated country codes | DE |
| ids | Array of Ids | The external institution identifiers associated with the author’s affiliation |
Reference
| Field | Type | Description | Example |
|---|---|---|---|
| lens_id | String | Unique lens identifier | 071-957-228-698-625 |
Open Access
| Field | Type | Description | Example |
|---|---|---|---|
| license | String | The Open Access license type | cc-by |
| colour | String | The Open Access colour category | gold |
Source
| Field | Type | Description | Example |
|---|---|---|---|
| title | String | The name of source publication in which the scholarly work appears | Journal name, Book title, Confernce proceedings |
| type | String | Source Type | Journal |
| publisher | String | The publisher of the source publication | W.B. Saunders Ltd |
| issn | Array of Object | ISSN | [{"value": "10797114"}] |
| country | String | The publisher’s country | United Kingdom |
| asjc_codes | String | The All Science Journal Classification (ASJC) code | 2735 |
| asjc_subjects | String | Subject is derived from journals descriptions in Crossref metadata based on the Science Journal Classification Codes | Pediatrics |
Mesh Term
| Field | Type | Description | Example |
|---|---|---|---|
| mesh_id | String | MeSH term unique identifier. MeSH terms are the National Library of Medicine’s controlled vocabulary or subject heading list. | D000293 |
| mesh_heading | String | MeSH terms are the National Library of Medicine’s controlled vocabulary or medical subject headings assigned to PubMed entries. NB MeSH Headings are case sensitive. | Adolescent |
| qualifier_id | String | Mesh Term Qualifier ID | Q000032 |
| qualifier_name | String | Mesh Term Qualifier Name | analysis |
ISSN
| Field | Type | Description | Example |
|---|---|---|---|
| value | String | The International Standard Serial Number | 10797114 |
| type | String | ISSN type | print, electronic |
Funding
| Field | Type | Description | Example |
|---|---|---|---|
| org | String | Name of the funding organisation | NIDCR NIH HHS |
| funding_id | String | The funding organisation’s project identifier | U01 DE018902 |
| country | String | The country of the funding body | United States |
Conference
| Field | Type | Description | Example |
|---|---|---|---|
| name | String | Conference Name | International Electron Devices Meeting |
| instance | String | Conference Instance Name | CHI 1985 |
| location | String | The location of the conference | Lihue, Kauai, HA, USA |
Chemical
| Field | Type | Description | Example |
|---|---|---|---|
| mesh_id | String | MeSH term id | D000293 |
| registry_number | String | Chemical registration number | 5Q7ZVV76EI |
| substance_name | String | Substance name | Antimalarials |
Clinical Trial
| Field | Type | Description | Example |
|---|---|---|---|
| id | String | Identifier | nct00105716 |
| registry | String | Clinical Trial Registry | 10.18810/clinical-trials-gov |
Source URL
| Field | Type | Description | Example |
|---|---|---|---|
| type | String | Source URL Type | html |
| url | String | URL String | http://cds.cern.ch/record/2291692 |
Ids
| Field | Type | Description | Example |
|---|---|---|---|
| type | String | The type/s of external identifiers for the scholarly work, author, institution, etc. | doi, pmid, magid, orcid, grid, ror, etc. |
| value | String | The external identifier(s) for the scholarly work, author, institution, etc. | 10.1016/s0031-3955(16)34861-1, 0000-0003-3902-2234, grid.425957.8, 056x7d368, etc. |
Enums
Publication Types
journal article, letter, editorial, news, book, book chapter, conference proceedings article, conference proceedings, dataset, journal, journal issue, journal volume, report, standard, dissertation, clinical trial, clinical study, libguide, reference entry, working paper, component, review, preprint, other, unknown
Sample API Response
Request:
{
"query":{
"match":{"lens_id":"086-713-276-176-892"}
}
}
Response:
{
"total": 1,
"max_score": 18.879501,
"data": [
{
"lens_id": "086-713-276-176-892",
"title": "A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer",
"publication_type": "journal article",
"year_published": 2015,
"date_published": "2015-06-13T00:00:00.000000+00:00",
"date_published_parts": [
2015,
6,
13
],
"created": "2018-05-12T02:39:28.395000+00:00",
"external_ids": [
{
"type": "pmcid",
"value": "pmc5024789"
},
{
"type": "coreid",
"value": "82196673"
},
{
"type": "magid",
"value": "2113210954"
},
{
"type": "pmid",
"value": "26082390"
},
{
"type": "doi",
"value": "10.1016/j.ejca.2015.05.019"
}
],
"patent_citations": [
{
"lens_id": "122-064-734-901-067"
}
],
"patent_citations_count": 1,
"open_access": {
"license": "cc-by-nc-nd",
"colour": "hybrid"
},
"authors": [
{
"first_name": "Maha",
"last_name": "Hussain",
"initials": "M",
"ids": [
{
"type": "magid",
"value": "2105158973"
}
],
"affiliations": [
{
"name": "University of Michigan",
"name_original": "University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States;",
"ids": [
{
"type": "magid",
"value": "27837315"
},
{
"type": "grid",
"value": "grid.214458.e"
},
{
"type": "fundref",
"value": "100007270"
},
{
"type": "ror",
"value": "00jmfr291"
}
],
"grid_id": "grid.214458.e",
"country_code": "US"
}
]
},
{
"first_name": "Dana E.",
"last_name": "Rathkopf",
"initials": "DE",
"ids": [
{
"type": "orcid",
"value": "0000-0002-4503-7582"
},
{
"type": "magid",
"value": "722834404"
}
],
"affiliations": [
{
"name": "Memorial Sloan Kettering Cancer Center",
"name_original": "Memorial Sloan Kettering New York NY United States",
"ids": [
{
"type": "magid",
"value": "1334819555"
},
{
"type": "grid",
"value": "grid.51462.34"
},
{
"type": "ror",
"value": "02yrq0923"
}
],
"grid_id": "grid.51462.34",
"country_code": "US"
}
]
},
{
"first_name": "Glenn",
"last_name": "Liu",
"initials": "G",
"ids": [
{
"type": "magid",
"value": "2133546628"
}
],
"affiliations": [
{
"name": "University of Wisconsin-Madison",
"name_original": "University of Wisconsin, Carbone Cancer Center, Madison, WI, United States.",
"ids": [
{
"type": "magid",
"value": "135310074"
},
{
"type": "grid",
"value": "grid.14003.36"
},
{
"type": "fundref",
"value": "100007015"
},
{
"type": "wikidata",
"value": "q838330"
},
{
"type": "ror",
"value": "01y2jtd41"
}
],
"grid_id": "grid.14003.36",
"country_code": "US"
}
]
},
{
"first_name": "Andrew J.",
"last_name": "Armstrong",
"initials": "AJ",
"ids": [
{
"type": "magid",
"value": "2172156363"
}
],
"affiliations": [
{
"name": "Duke University",
"name_original": "Duke Cancer Institute and Duke Prostate Center, Duke University, Durham, NC, United States",
"ids": [
{
"type": "magid",
"value": "170897317"
},
{
"type": "grid",
"value": "grid.26009.3d"
},
{
"type": "fundref",
"value": "100006510"
},
{
"type": "wikidata",
"value": "q168751"
},
{
"type": "ror",
"value": "00py81415"
}
],
"grid_id": "grid.26009.3d",
"country_code": "US"
}
]
},
{
"first_name": "Kevin",
"last_name": "Kelly",
"initials": "K",
"ids": [
{
"type": "magid",
"value": "2097407452"
}
],
"affiliations": [
{
"name": "Thomas Jefferson University",
"name_original": "Thomas Jefferson Univ., Philadelphia, PA (United States)",
"ids": [
{
"type": "magid",
"value": "149251103"
},
{
"type": "grid",
"value": "grid.265008.9"
},
{
"type": "ror",
"value": "00ysqcn41"
}
],
"grid_id": "grid.265008.9",
"country_code": "US"
}
]
},
{
"first_name": "Anna C.",
"last_name": "Ferrari",
"initials": "AC",
"ids": [
{
"type": "magid",
"value": "2312728207"
}
],
"affiliations": [
{
"name": "New York University",
"name_original": "New York University Clinical Cancer Center, New York, NY, United States.",
"ids": [
{
"type": "magid",
"value": "57206974"
},
{
"type": "grid",
"value": "grid.137628.9"
},
{
"type": "fundref",
"value": "100006732"
},
{
"type": "wikidata",
"value": "q49210"
},
{
"type": "ror",
"value": "0190ak572"
}
],
"grid_id": "grid.137628.9",
"country_code": "US"
}
]
},
{
"first_name": "John D.",
"last_name": "Hainsworth",
"initials": "JD",
"ids": [
{
"type": "magid",
"value": "2145549068"
}
],
"affiliations": [
{
"name": "Sarah Cannon Research Institute",
"name_original": "Sarah Cannon Research Institute, Nashville, TN, United States",
"ids": [
{
"type": "magid",
"value": "172427033"
},
{
"type": "grid",
"value": "grid.477834.b"
},
{
"type": "wikidata",
"value": "q30270369"
},
{
"type": "ror",
"value": "03cp5cj42"
}
],
"grid_id": "grid.477834.b",
"country_code": "GB"
}
]
},
{
"first_name": "Adarsh",
"last_name": "Joshi",
"initials": "A",
"ids": [
{
"type": "magid",
"value": "2097035297"
}
],
"affiliations": [
{
"name": "Eli Lilly and Company",
"name_original": "Eli Lilly and Company, Bridgewater, NJ, United States.",
"ids": [
{
"type": "magid",
"value": "168537998"
},
{
"type": "grid",
"value": "grid.417540.3"
},
{
"type": "fundref",
"value": "100004312"
},
{
"type": "ror",
"value": "01qat3289"
}
],
"grid_id": "grid.417540.3",
"country_code": "US"
}
]
},
{
"first_name": "Rebecca R.",
"last_name": "Hozak",
"initials": "RR",
"ids": [
{
"type": "magid",
"value": "2182553763"
}
],
"affiliations": [
{
"name": "Eli Lilly and Company",
"name_original": "Eli Lilly and Company, Indianapolis, IN (United States)",
"ids": [
{
"type": "magid",
"value": "168537998"
},
{
"type": "grid",
"value": "grid.417540.3"
},
{
"type": "fundref",
"value": "100004312"
},
{
"type": "ror",
"value": "01qat3289"
}
],
"grid_id": "grid.417540.3",
"country_code": "US"
}
]
},
{
"first_name": "Ling",
"last_name": "Yang",
"initials": "L",
"ids": [
{
"type": "magid",
"value": "2250633597"
}
],
"affiliations": [
{
"name": "Eli Lilly and Company",
"name_original": "Eli Lilly and Company, Bridgewater, NJ, United States.",
"ids": [
{
"type": "magid",
"value": "168537998"
},
{
"type": "grid",
"value": "grid.417540.3"
},
{
"type": "fundref",
"value": "100004312"
},
{
"type": "ror",
"value": "01qat3289"
}
],
"grid_id": "grid.417540.3",
"country_code": "US"
}
]
},
{
"first_name": "Jonathan D.",
"last_name": "Schwartz",
"initials": "JD",
"ids": [
{
"type": "magid",
"value": "2155041711"
}
],
"affiliations": [
{
"name": "Eli Lilly and Company",
"name_original": "Eli Lilly and Company, Bridgewater, NJ, United States.",
"ids": [
{
"type": "magid",
"value": "168537998"
},
{
"type": "grid",
"value": "grid.417540.3"
},
{
"type": "fundref",
"value": "100004312"
},
{
"type": "ror",
"value": "01qat3289"
}
],
"grid_id": "grid.417540.3",
"country_code": "US"
}
]
},
{
"first_name": "Celestia S.",
"last_name": "Higano",
"initials": "CS",
"ids": [
{
"type": "magid",
"value": "2560077320"
}
],
"affiliations": [
{
"name": "Fred Hutchinson Cancer Research Center",
"name_original": "University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, United States",
"ids": [
{
"type": "grid",
"value": "grid.270240.3"
},
{
"type": "ror",
"value": "007ps6h72"
}
],
"grid_id": "grid.270240.3",
"country_code": "US"
},
{
"name": "University of Washington",
"name_original": "University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, United States",
"ids": [
{
"type": "fundref",
"value": "100007812"
},
{
"type": "orgref",
"value": "31776"
},
{
"type": "grid",
"value": "grid.34477.33"
},
{
"type": "ror",
"value": "00cvxb145"
}
],
"grid_id": "grid.34477.33",
"country_code": "US"
}
]
}
],
"source": {
"title": "European journal of cancer (Oxford, England : 1990)",
"type": "Journal",
"publisher": "Elsevier Limited",
"issn": [
{
"type": "unknown",
"value": "18790852"
},
{
"type": "print",
"value": "09598049"
}
],
"country": "United Kingdom",
"asjc_codes": [
"1306",
"2730"
],
"asjc_subjects": [
"Cancer Research",
"Oncology"
]
},
"fields_of_study": [
"Internal medicine",
"Oncology",
"Cixutumumab",
"Prednisone",
"Ramucirumab",
"Prostate cancer",
"Mitoxantrone",
"Docetaxel",
"Regimen",
"Phases of clinical research",
"Medicine"
],
"keywords": [
"Cixutumumab",
"Mitoxantrone",
"Prednisone",
"Prostate cancer",
"Ramucirumab"
],
"publication_supplementary_type": [
"clinical trial, phase ii",
"multicenter study",
"randomized controlled trial",
"research support, non-u.s. gov't"
],
"volume": "51",
"issue": "13",
"languages": [
"en"
],
"references": [
{
"lens_id": "003-415-704-045-340"
},
{
"lens_id": "006-027-163-131-418"
},
{
"lens_id": "010-839-632-959-305"
},
{
"lens_id": "013-690-046-069-453"
},
{
"lens_id": "015-449-984-502-884"
},
{
"lens_id": "015-767-931-570-158"
},
{
"lens_id": "018-245-327-947-052"
},
{
"lens_id": "020-963-415-260-304"
},
{
"lens_id": "026-332-934-265-841"
},
{
"lens_id": "028-101-820-366-93X"
},
{
"lens_id": "032-523-762-689-478"
},
{
"lens_id": "037-117-740-052-570"
},
{
"lens_id": "038-557-040-762-884"
},
{
"lens_id": "040-239-601-782-040"
},
{
"lens_id": "042-246-996-698-043"
},
{
"lens_id": "043-024-349-674-734"
},
{
"lens_id": "043-201-312-439-671"
},
{
"lens_id": "043-546-849-370-25X"
},
{
"lens_id": "046-041-414-632-674"
},
{
"lens_id": "046-648-350-541-685"
},
{
"lens_id": "046-852-526-558-260"
},
{
"lens_id": "054-808-246-993-497"
},
{
"lens_id": "059-727-763-246-876"
},
{
"lens_id": "065-982-455-260-233"
},
{
"lens_id": "069-612-901-254-771"
},
{
"lens_id": "070-794-057-102-152"
},
{
"lens_id": "083-233-359-584-62X"
},
{
"lens_id": "087-375-055-670-659"
},
{
"lens_id": "087-458-139-690-01X"
},
{
"lens_id": "090-234-280-758-859"
},
{
"lens_id": "094-489-992-059-749"
},
{
"lens_id": "096-654-301-744-608"
},
{
"lens_id": "101-625-667-760-940"
},
{
"lens_id": "113-073-836-369-700"
},
{
"lens_id": "128-335-721-572-401"
},
{
"lens_id": "155-152-241-876-905"
}
],
"mesh_terms": [
{
"mesh_heading": "Adenocarcinoma",
"qualifier_name": "drug therapy",
"mesh_id": "D000230",
"qualifier_id": "Q000188"
},
{
"mesh_heading": "Adolescent",
"mesh_id": "D000293"
},
{
"mesh_heading": "Adult",
"mesh_id": "D000328"
},
{
"mesh_heading": "Aged",
"mesh_id": "D000368"
},
{
"mesh_heading": "Antibodies, Monoclonal",
"qualifier_name": "administration & dosage",
"mesh_id": "D000911",
"qualifier_id": "Q000008"
},
{
"mesh_heading": "Antibodies, Monoclonal, Humanized",
"mesh_id": "D061067"
},
{
"mesh_heading": "Antineoplastic Combined Chemotherapy Protocols",
"qualifier_name": "adverse effects",
"mesh_id": "D000971",
"qualifier_id": "Q000009"
},
{
"mesh_heading": "Disease Progression",
"mesh_id": "D018450"
},
{
"mesh_heading": "Disease-Free Survival",
"mesh_id": "D018572"
},
{
"mesh_heading": "Docetaxel",
"mesh_id": "D000077143"
},
{
"mesh_heading": "Humans",
"mesh_id": "D006801"
},
{
"mesh_heading": "Kaplan-Meier Estimate",
"mesh_id": "D053208"
},
{
"mesh_heading": "Male",
"mesh_id": "D008297"
},
{
"mesh_heading": "Middle Aged",
"mesh_id": "D008875"
},
{
"mesh_heading": "Mitoxantrone",
"qualifier_name": "administration & dosage",
"mesh_id": "D008942",
"qualifier_id": "Q000008"
},
{
"mesh_heading": "Prednisone",
"qualifier_name": "administration & dosage",
"mesh_id": "D011241",
"qualifier_id": "Q000008"
},
{
"mesh_heading": "Proportional Hazards Models",
"mesh_id": "D016016"
},
{
"mesh_heading": "Prostatic Neoplasms, Castration-Resistant",
"qualifier_name": "drug therapy",
"mesh_id": "D064129",
"qualifier_id": "Q000188"
},
{
"mesh_heading": "Taxoids",
"qualifier_name": "therapeutic use",
"mesh_id": "D043823",
"qualifier_id": "Q000627"
},
{
"mesh_heading": "Time Factors",
"mesh_id": "D013997"
},
{
"mesh_heading": "Treatment Outcome",
"mesh_id": "D016896"
},
{
"mesh_heading": "United States",
"mesh_id": "D014481"
},
{
"mesh_heading": "Young Adult",
"mesh_id": "D055815"
}
],
"chemicals": [
{
"substance_name": "Antibodies, Monoclonal",
"registry_number": "0",
"mesh_id": "D000911"
},
{
"substance_name": "Antibodies, Monoclonal, Humanized",
"registry_number": "0",
"mesh_id": "D061067"
},
{
"substance_name": "Taxoids",
"registry_number": "0",
"mesh_id": "D043823"
},
{
"substance_name": "Docetaxel",
"registry_number": "15H5577CQD",
"mesh_id": "D000077143"
},
{
"substance_name": "cixutumumab",
"registry_number": "2285XW22DR",
"mesh_id": "C557414"
},
{
"substance_name": "Mitoxantrone",
"registry_number": "BZ114NVM5P",
"mesh_id": "D008942"
},
{
"substance_name": "ramucirumab",
"registry_number": "D99YVK4L0X",
"mesh_id": "C543333"
},
{
"substance_name": "Prednisone",
"registry_number": "VB0R961HZT",
"mesh_id": "D011241"
}
],
"clinical_trials": [
{
"id": "nct00683475",
"registry": "10.18810/clinical-trials-gov"
}
],
"funding": [
{
"org": "NCI NIH HHS",
"funding_id": "P30 CA008748",
"country": "United States"
}
],
"source_urls": [
{
"type": "html",
"url": "https://www.scholars.northwestern.edu/en/publications/a-randomised-non-comparative-phase-ii-trial-of-cixutumumab-imc-a1"
},
{
"type": "html",
"url": "https://www.sciencedirect.com/science/article/pii/S0959804915004505"
},
{
"type": "html",
"url": "https://core.ac.uk/display/82196673"
},
{
"type": "html",
"url": "https://www.ncbi.nlm.nih.gov/pubmed/26082390"
},
{
"type": "html",
"url": "https://europepmc.org/abstract/MED/26082390"
},
{
"type": "html",
"url": "https://pubmed.ncbi.nlm.nih.gov/26082390/"
},
{
"type": "unknown",
"url": "https://www.sciencedirect.com/science/article/abs/pii/S0959804915004505#!"
},
{
"type": "core_fulltext",
"url": "https://core.ac.uk/download/pdf/82196673.pdf"
}
],
"abstract": "Abstract Background Cixutumumab, a human monoclonal antibody (HuMAb), targets the insulin-like growth factor receptor. Ramucirumab is a recombinant HuMAb that binds to vascular endothelial growth factor receptor-2. A non-comparative randomised phase II study evaluated cixutumumab or ramucirumab plus mitoxantrone and prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC). Patients and methods Men with progressive mCRPC during or after docetaxel therapy received mitoxantrone 12 mg/m2 on day 1 and prednisone 5 mg twice daily and were randomised 1:1 to receive either cixutumumab or ramucirumab 6 mg/kg intravenously weekly in a 21-day cycle. Primary end-point was composite progression-free survival (cPFS). Secondary end-points included safety, response, radiographic progression-free survival (PFS) and overall survival (OS). Sample size was based on a 50% increase in median cPFS from 2.6 (MP) to 3.9 months (either combination). Results 132 men were treated (66 per arm). Median cPFS was 4.1 months (95% confidence interval (CI), 2.2–5.6) for cixutumumab and 6.7 months (95% CI, 4.5–8.3) for ramucirumab. Median time to radiographic progression was 7.5 months for cixutumumab and 10.2 months for ramucirumab, with a median OS of 10.8 and 13.0 months, respectively. Fatigue was the most frequent adverse event (AE). Incidence of most non-haematologic grade 3–4 AEs was Conclusion Combinations of cixutumumab or ramucirumab plus MP were feasible and associated with moderate toxicities in docetaxel-pretreated men with mCRPC. Of the two regimens, the ramucirumab regimen is worthy of further testing based on the observed cPFS relative to the historical control.",
"references_count": 36,
"scholarly_citations_count": 27,
"start_page": "1714",
"end_page": "1724",
"scholarly_citations": [
"000-201-187-558-654",
"003-526-658-910-015",
"003-873-121-875-383",
"007-302-126-599-214",
"010-213-946-021-323",
"013-615-059-072-408",
"013-724-699-030-436",
"014-223-693-822-29X",
"018-109-129-610-567",
"021-609-846-309-864",
"026-107-871-228-662",
"026-389-814-274-812",
"028-262-672-178-175",
"030-115-779-382-725",
"035-630-845-016-108",
"037-016-998-061-439",
"041-068-995-918-23X",
"046-312-772-821-709",
"054-371-103-868-542",
"055-935-439-115-752",
"062-343-220-167-149",
"067-043-485-486-441",
"085-619-841-835-92X",
"086-063-652-233-255",
"132-091-200-995-616",
"145-126-752-104-913",
"153-500-774-834-922"
],
"author_count": 12,
"is_open_access": true
}
],
"results": 1
}